First Foundation Labs Collaborates with Microsoft to Enhance AI-Driven Clinical and Translational Reasoning
3 June 2026
First Foundation Labs (1FL), a life sciences artificial intelligence company established by Luma Group, has announced a collaboration with Microsoft to support the development and enterprise deployment of its reasoning platform through Microsoft Discovery. The platform, built on Microsoft Azure, is designed to accelerate scientific research, research and development activities, and advanced scientific computing.
The collaboration aims to address the limitations of general-purpose large language models, which often struggle to analyse and reason within highly specialised life sciences environments. Such environments require the interpretation of complex biological, clinical and translational data that exist within interconnected and constantly evolving systems.
1FL is developing AI systems specifically designed for life sciences reasoning. Its platform combines clinical, translational and cross-domain intelligence to help researchers make more informed decisions throughout the drug development process.
Microsoft Discovery provides life sciences research teams with tools for knowledge reasoning, hypothesis generation, experimental simulation and iterative learning. Through the collaboration, 1FL will add clinical and translational reasoning capabilities to the platform, creating a continuous intelligence layer that supports activities from early-stage drug discovery through to commercialisation.
The companies stated that the partnership will combine Microsoft’s AI infrastructure and enterprise-scale capabilities with 1FL’s specialised life sciences reasoning technology. The goal is to enable AI systems to analyse a broader range of factors involved in drug development, including clinical outcomes, regulatory requirements and competitive considerations.
The collaboration is also expected to strengthen hypothesis generation and support decision-making across the research and development lifecycle, helping life sciences organisations advance the discovery and development of new therapies.
Source: prnewswire.com
